NASDAQ: ALLRAllarity Therapeutics Inc Stock
$1.10+0.03 (+2.8%)
Updated May 20, 2025
ALLR Price
$1.10
Fair Value Price
N/A
Market Cap
$16.59M
52 Week Low
$0.61
52 Week High
$20.44
P/E
-0.7x
P/B
0.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.59
Operating Cash Flow
-$19M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALLR Overview
Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer. The company uses Drug Response Predictor (DRP®) technology to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures. Its pipeline products include Dovitinib, Stenoparib, Ixempra, and other formulations. Allarity was incorporated in 2004 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALLR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALLR
Ranked#195 of 454
Ranked#195 of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.20 | A | |
| $8.30 | A | |
| $65.30 | A |
Be the first to know about important ALLR news, forecast changes, insider trades & much more!
ALLR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALLR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALLR is good value based on its book value relative to its share price (0.89x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALLR due diligence checks available for Premium users.
Valuation
ALLR fair value
Fair Value of ALLR stock based on Discounted Cash Flow (DCF)
Price
$1.10
Fair Value
$0.01
Overvalued by
11,110.89%
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALLR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
-156.07x
Market
25.56x
ALLR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
4.37x
ALLR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALLR's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
ALLR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$29.7M
Liabilities
$11.1M
Debt to equity
0.59
ALLR's short-term assets ($29.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLR's short-term assets ($29.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$0.0
Financing
$11.1M
ALLR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALLR vs Biotech Stocks
Allarity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.